Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial

BACKGROUND: Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a serious, often life-threatening disease. In new-onset disease or a relapse, the standard treatment is immunosuppressive therapy with glucocorticoids; these therapies are associated with substantial short- and long-term...

Descripción completa

Detalles Bibliográficos
Autores principales: Merkel, Peter A, Jayne, David R, Wang, Chao, Hillson, Jan, Bekker, Pirow
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2020
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175182/
https://www.ncbi.nlm.nih.gov/pubmed/32088663
http://dx.doi.org/10.2196/16664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175182/
https://www.ncbi.nlm.nih.gov/pubmed/32088663
http://dx.doi.org/10.2196/16664

Ejemplares similares